2026-09-22 Analyst Bull
Cantor note says Tango market cap highly discounted Analyst Schmidt lists 5 underestimated factors; ~$4B cap seen discounted vs de-risked story
D1 +14.3% · +5d -4.3%
2026-08-18 Analyst Bull
Stifel reiterates Buy $40; ESMO data and PDAC Ph3 in focus Mgmt hints vopimetostat+RAS(ON) combo data at ESMO 2026; 3 catalysts by YE26 highlighted
D1 +0.6% · +5d -2.6%
14 earlier events › 2026-08-12 Earnings Bear
Q2 Loss Wider Than Expected, Stock Dips 5% Higher operating expenses drove wider loss; pipeline progress remains in focus
D1 -2.9% · +5d -1.5%
2026-08-12 8-K filing
8-K: Item 8.01, Item 9.01 D1 -2.9% · +5d -1.5%
2026-08-12 Analyst Bull
Mizuho Reiterates $40 PT, Sees Combo Potential PFS data, oral-oral combo, and PDAC potential support rating
D1 -2.9% · +5d -1.5%
2026-08-11 Earnings
Earnings report D1 -4.8% · +5d -3.4%
2026-08-11 8-K filing
8-K: Item 2.02, Item 9.01 D1 -4.8% · +5d -3.4%
2026-08-10 Earnings
Earnings report D1 +2.2% · +5d -8.6%
2026-08-06 8-K filing
8-K: Item 5.02 D1 +0.7% · +5d -11.6%
2026-08-04 Earnings
Earnings report D1 +7.9% · +5d -10.3%
2026-08-03 Analyst Bull
Analysts Give Tango Therapeutics 'Moderate Buy' Average Rating 16 research firms covering the stock, average rating of 'Moderate Buy'
D1 +0.1% · +5d +1.7%
2026-06-26 Analyst
Jefferies upgrades to Buy D1 +4.4% · +5d -4.9%
2026-06-23 8-K filing
8-K: Item 5.02, Item 9.01 D1 -0.4% · +5d +10.1%
2026-06-08 → 06-13 Product Bull
TNGX Dual Combo Pancreatic Data Triggers Biotech M&A Speculation Analysts highlight pan-RAS(ON)+PRMT5 pairing as path forward, cite M&A potential
D1 +53.0% · +5d +6.4%
› 2 waves of this story2026-06-08 Multiple sources discuss high response rate and 90% 6-month PFS in pancreatic cancer combo2026-06-13 Analysts highlight pan-RAS(ON)+PRMT5 pairing as path forward, cite M&A potential2026-06-10 8-K filing
8-K: Item 1.01, Item 9.01 D1 -9.1% · +5d +12.6%
2026-06-08 8-K filing
8-K: Item 7.01, Item 8.01, Item 9.01 D1 +53.0% · +5d +6.4%
by direction · sourced
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
be the first
🙂 Post
Facts and opinions separated · All items sourced · Not investment advice
